These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36892094)

  • 1. Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension.
    Chang KY; Giorgio K; Schmitz K; Walker RF; Prins KW; Pritzker MR; Archer SL; Lutsey PL; Thenappan T
    J Am Heart Assoc; 2023 Mar; 12(6):e027559. PubMed ID: 36892094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 3. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure.
    Meyer P; White M; Mujib M; Nozza A; Love TE; Aban I; Young JB; Wehrmacher WH; Ahmed A
    Am J Cardiol; 2008 Dec; 102(12):1681-6. PubMed ID: 19064024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction.
    Zhou J; Cao J; Jin X; Zhou J; Chen Z; Xu D; Yang X; Dong W; Li L; Fan Y; Chen L; Zhong Q; Fu M; Hu K; Ge J;
    ESC Heart Fail; 2020 Feb; 7(1):138-146. PubMed ID: 31994361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis.
    Thenappan T; Roy SS; Duval S; Glassner-Kolmin C; Gomberg-Maitland M
    Circ Heart Fail; 2014 Nov; 7(6):903-10. PubMed ID: 25277998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of composite clinical worsening events on outcome of patients with pulmonary arterial hypertension associated with congenital heart disease].
    Xu ZY; Zhang HS; Li QQ; Zhang C; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Mar; 50(3):282-288. PubMed ID: 35340148
    [No Abstract]   [Full Text] [Related]  

  • 7. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure.
    Shah M; Avgil Tsadok M; Jackevicius CA; Essebag V; Behlouli H; Pilote L
    Am J Cardiol; 2014 Aug; 114(3):401-6. PubMed ID: 24950677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy.
    Georgiopoulou VV; Kalogeropoulos AP; Giamouzis G; Agha SA; Rashad MA; Waheed S; Laskar S; Smith AL; Butler J
    Circ Heart Fail; 2009 Mar; 2(2):90-7. PubMed ID: 19808323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between the risk of heart failure hospitalization and end-stage renal disease with digoxin usage in patients with cardiorenal syndrome: A population-based study.
    Chang KT; Kuo HF; Chang YH; Wang YT; Yang LJ; Niu SW; Kuo IC; Chen Y; Wen ZH; Hung CC; Chang JM; Lin HY
    Front Public Health; 2022; 10():1074017. PubMed ID: 36733284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial.
    Lee AY; Kutyifa V; Ruwald MH; McNitt S; Polonsky B; Zareba W; Moss AJ; Ruwald AC
    Heart Rhythm; 2015 Sep; 12(9):2010-7. PubMed ID: 26025322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension.
    So PP; Davies RA; Chandy G; Stewart D; Beanlands RS; Haddad H; Pugliese C; Mielniczuk LM
    Am J Cardiol; 2012 May; 109(10):1504-9. PubMed ID: 22385756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.
    Mulder BA; Van Veldhuisen DJ; Crijns HJ; Tijssen JG; Hillege HL; Alings M; Rienstra M; Van den Berg MP; Van Gelder IC;
    Heart Rhythm; 2014 Sep; 11(9):1543-50. PubMed ID: 24924587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study.
    Madelaire C; Schou M; Nelveg-Kristensen KE; Schmiegelow M; Torp-Pedersen C; Gustafsson F; Køber L; Gislason G
    Int J Cardiol; 2016 Oct; 221():944-50. PubMed ID: 27441473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes in patients with atrial fibrillation treated with digoxin, according to the presence of heart failure: Insights from the MISOAC-AF trial.
    Botis M; Kartas A; Samaras A; Akrivos E; Vrana E; Liampas E; Papazoglou AS; Moysidis DV; Papanastasiou A; Baroutidou A; Karvounis H; Tzikas A; Parissis J; Drakos SG; Giannakoulas G
    Hellenic J Cardiol; 2022; 68():25-32. PubMed ID: 36037999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.
    Ambrosy AP; Bhatt AS; Stebbins AL; Wruck LM; Fudim M; Greene SJ; Kraus WE; O'Connor CM; Piña IL; Whellan DJ; Mentz RJ
    Am Heart J; 2018 May; 199():97-104. PubMed ID: 29754673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data.
    Ather S; Peterson LE; Divakaran VG; Deswal A; Ramasubbu K; Giorgberidze I; Blaustein A; Wehrens XH; Mann DL; Bozkurt B
    Int J Cardiol; 2011 Aug; 150(3):264-9. PubMed ID: 20471706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digoxin and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction (HFpEF) Patients: A Systematic Review and Meta- Analysis.
    Hashemi-Shahri SH; Aghajanloo A; Ghavami V; Arasteh O; Mohammadpour AH; Reiner Ž; Sahebkar A
    Curr Drug Targets; 2023; 24(2):191-200. PubMed ID: 36065922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients.
    Kalogeropoulos AP; Siwamogsatham S; Hayek S; Li S; Deka A; Marti CN; Georgiopoulou VV; Butler J
    J Am Heart Assoc; 2014 Feb; 3(1):e000363. PubMed ID: 24492947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Tremblay É; Gosselin C; Mai V; Lajoie AC; Kilo R; Weatherald J; Lacasse Y; Bonnet S; Lega JC; Provencher S
    Circulation; 2022 Aug; 146(8):597-612. PubMed ID: 35862151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
    Tsang Y; Stokes M; Kim YJ; Tilney R; Panjabi S
    Clin Respir J; 2023 Dec; 17(12):1209-1222. PubMed ID: 37804160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.